Shares of Cencora, Inc. (NYSE:COR – Get Free Report) have received an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $258.63.
Several equities research analysts recently weighed in on COR shares. SVB Leerink restated an “outperform” rating and set a $275.00 target price on shares of Cencora in a research note on Thursday, June 27th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday. Wells Fargo & Company lifted their price target on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. StockNews.com upgraded shares of Cencora from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Finally, Citigroup raised their price objective on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th.
Read Our Latest Report on Cencora
Insider Transactions at Cencora
Institutional Investors Weigh In On Cencora
Several institutional investors have recently made changes to their positions in COR. Rise Advisors LLC acquired a new stake in shares of Cencora in the first quarter valued at about $25,000. Legacy Bridge LLC purchased a new position in Cencora in the first quarter valued at about $27,000. New Millennium Group LLC acquired a new stake in shares of Cencora during the 2nd quarter valued at approximately $26,000. TCTC Holdings LLC purchased a new stake in shares of Cencora during the 1st quarter worth approximately $29,000. Finally, TFO Wealth Partners LLC acquired a new stake in shares of Cencora in the 1st quarter worth approximately $30,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.
Cencora Trading Down 1.2 %
NYSE COR opened at $237.74 on Friday. Cencora has a 52 week low of $171.65 and a 52 week high of $247.66. The firm has a 50 day moving average of $231.85 and a two-hundred day moving average of $232.81. The stock has a market capitalization of $47.42 billion, a PE ratio of 26.01, a price-to-earnings-growth ratio of 1.68 and a beta of 0.45. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.93.
Cencora (NYSE:COR – Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. The firm had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.92 earnings per share. As a group, research analysts expect that Cencora will post 13.56 EPS for the current fiscal year.
Cencora Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, August 26th. Shareholders of record on Friday, August 9th will be paid a $0.51 dividend. The ex-dividend date is Friday, August 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.86%. Cencora’s dividend payout ratio (DPR) is currently 22.32%.
About Cencora
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles
- Five stocks we like better than Cencora
- EV Stocks and How to Profit from Them
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- What Are the FAANG Stocks and Are They Good Investments?
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- How to Buy Cheap Stocks Step by Step
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.